Comment on Yoo et al. Amylin Protein Expression in the Rat Brain and Neuro-2a Cells. Int. J. Mol. Sci. 2022, 23, 4348

We read with great interest the recent article by Yoo and colleagues [1] titled “Amylin Protein Expression in the Rat Brain and Neuro-2a Cells”. This study investigated the distribution of amylin-like immunoreactivity throughout the rat brain, a subject of growing clinical interest. One of the major findings was the widespread expression of amylin in regions of the rat brain linked to both metabolism and pain. However, caution needs to be taken when interpreting the clinical translatability and impact of these findings due to limitations in the methodology.

The specific detection of amylin expression in nervous tissue is challenging due to the abundance of calcitonin gene-related peptides (CGRP). Some mRNA and antibody-based tools are unable to sufficiently distinguish between these two related peptides [2,3,4,5]. We recently highlighted this issue by investigating the cross-reactivity between amylin and CGRP for several anti-amylin antibodies which had previously been used in human and rodent nervous tissues. We observed that all of the anti-amylin antibodies that could effectively detect amylin also displayed variable cross-reactivity with physiologically relevant concentrations of rodent αCGRP [6]. We then used an amylin-specific antibody to show that any amylin-like staining in human trigeminal ganglia neurons was likely due to cross-reactivity with CGRP [7]. These data, together with historical reports, build a compelling argument that researchers must consider the potential contribution of CGRP to immunoreactivity detected using anti-amylin antibodies in the nervous system.

Yoo and colleagues acknowledge the significant complication CGRP cross-reactivity has caused for the identification of amylin in the nervous system. However, it is unclear how this issue has been addressed in this study. The potential contribution of CGRP to their observed amylin-like immunoreactivity must be considered because CGRP mRNA and/or protein are widespread in the brain and have been described in many of the regions investigated [8]. For example, the cerebellar and brainstem amylin immunoreactivity patterns presented by Yoo and colleagues in figure 1 strongly resemble previous reports of CGRP in these regions [9,10]. In contrast, amylin mRNA and protein have much more restricted expression, such as in the preoptic area of the hypothalamus [11,12,13,14]. Although Yoo and colleagues do not state the exact region of the hypothalamus investigated, genuine amylin staining could be present in this location. Interestingly, comparatively few anti-CGRP antibodies appear to exhibit cross-reactivity with amylin [15]. This suggests that the cross-reactivity of anti-CGRP antibodies with amylin is less likely to be a confounding consideration in interpreting CGRP expression in the nervous system.

An alternative conclusion to the immunoreactivity observed by Yoo and colleagues being the detection of amylin is that some or all of the immunoreactivity is instead cross-reactive detection of CGRP. This is supported by the author’s discussion, which notes the similarity of their anti-amylin antibody to T4157, which is known to be highly cross-reactive with CGRP [6,16]. Given this, the findings of this study should be interpreted cautiously with CGRP in mind.

Conflicts of Interest

The authors declare the following conflicts of interest. DLH is or has been a consultant or speaker for Lilly, Amgen, Teva, Intarcia, Merck Sharp & Dohme and has received research funding from Living Cell Technologies and AbbVie in the past three years. CSW has re-ceived research support from Living Cell Technologies and AbbVie.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Yoo, Y.-M.; Jung, E.-M.; Jeung, E.-B.; Jo, B.R.; Joo, S.S. Amylin Protein Expression in the Rat Brain and Neuro-2a Cells. Int. J. Mol. Sci.; 2022; 23, 4348. [DOI: https://dx.doi.org/10.3390/ijms23084348] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35457166]

2. Ahren, B.; Sundler, F. Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. Cell Tissue Res.; 1992; 269, pp. 315-322. [DOI: https://dx.doi.org/10.1007/BF00319623] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1423499]

3. Ferrier, G.J.; Pierson, A.M.; Jones, P.M.; Bloom, S.R.; Girgis, S.I.; Legon, S. Expression of the rat amylin (IAPP/DAP) gene. J. Mol. Endocrinol.; 1989; 3, pp. R1-R4. [DOI: https://dx.doi.org/10.1677/jme.0.003R001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2525914]

4. Nicholl, C.G.; Bhatavdekar, J.M.; Mak, J.; Girgis, S.I.; Legon, S. Extra-pancreatic expression of the rat islet amyloid polypeptide (amylin) gene. J. Mol. Endocrinol.; 1992; 9, pp. 157-163. [DOI: https://dx.doi.org/10.1677/jme.0.0090157] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1418386]

5. Tingstedt, J.E.; Edlund, H.; Madsen, O.D.; Larsson, L.I. Gastric amylin expression. Cellular identity and lack of requirement for the homeobox protein PDX-1. A study in normal and PDX-1-deficient animals with a cautionary note on antiserum evaluation. J. Histochem. Cytochem.; 1999; 47, pp. 973-980. [DOI: https://dx.doi.org/10.1177/002215549904700801] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10424881]

6. Rees, T.A.; Hay, D.L.; Walker, C.S. Amylin antibodies frequently display cross-reactivity with CGRP: Characterization of eight amylin antibodies. Am. J. Physiol. Regul. Integr. Comp. Physiol.; 2021; 320, pp. R697-R703. [DOI: https://dx.doi.org/10.1152/ajpregu.00338.2020] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33565362]

7. Ghanizada, H.; Al-Karagholi, M.A.; Walker, C.S.; Arngrim, N.; Rees, T.; Petersen, J.; Siow, A.; Morch-Rasmussen, M.; Tan, S.; O’Carroll, S.J. et al. Amylin analog pramlintide induces migraine-like attacks in patients. Ann. Neurol.; 2021; 89, pp. 1157-1171. [DOI: https://dx.doi.org/10.1002/ana.26072] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33772845]

8. Hendrikse, E.R.; Bower, R.L.; Hay, D.L.; Walker, C.S. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia; 2019; 39, pp. 403-419. [DOI: https://dx.doi.org/10.1177/0333102418765787] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29566540]

9. Eftekhari, S.; Salvatore, C.A.; Gaspar, R.C.; Roberts, R.; O’Malley, S.; Zeng, Z.; Edvinsson, L. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum; 2013; 12, pp. 937-949. [DOI: https://dx.doi.org/10.1007/s12311-013-0509-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23917876]

10. Unger, J.W.; Lange, W. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J. Chem. Neuroanat.; 1991; 4, pp. 299-309. [DOI: https://dx.doi.org/10.1016/0891-0618(91)90020-D] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1930749]

11. Dobolyi, A. Central amylin expression and its induction in rat dams. J. Neurochem.; 2009; 111, pp. 1490-1500. [DOI: https://dx.doi.org/10.1111/j.1471-4159.2009.06422.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19811608]

12. Fukumitsu, K.; Kaneko, M.; Maruyama, T.; Yoshihara, C.; Huang, A.J.; McHugh, T.J.; Itohara, S.; Tanaka, M.; Kuroda, K.O. Amylin-Calcitonin receptor signaling in the medial preoptic area mediates affiliative social behaviors in female mice. Nat. Commun.; 2022; 13, 709. [DOI: https://dx.doi.org/10.1038/s41467-022-28131-z] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35136064]

13. Gerecsei, L.I.; Csillag, A.; Zachar, G.; Gevai, L.; Simon, L.; Dobolyi, A.; Adam, A. Gestational Exposure to the Synthetic Cathinone Methylenedioxypyrovalerone Results in Reduced Maternal Care and Behavioral Alterations in Mouse Pups. Front. Neurosci.; 2018; 12, 27. [DOI: https://dx.doi.org/10.3389/fnins.2018.00027] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29459818]

14. Yoshihara, C.; Tokita, K.; Maruyama, T.; Kaneko, M.; Tsuneoka, Y.; Fukumitsu, K.; Miyazawa, E.; Shinozuka, K.; Huang, A.J.; Nishimori, K. et al. Calcitonin receptor signaling in the medial preoptic area enables risk-taking maternal care. Cell Rep.; 2021; 35, 109204. [DOI: https://dx.doi.org/10.1016/j.celrep.2021.109204] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34077719]

15. Rees, T.A.; Russo, A.F.; O’Carroll, S.J.; Hay, D.L.; Walker, C.S. CGRP and the Calcitonin Receptor are Co-Expressed in Mouse, Rat and Human Trigeminal Ganglia Neurons. Front. Physiol.; 2022; 13, 860037. [DOI: https://dx.doi.org/10.3389/fphys.2022.860037]

16. Verma, N.; Ly, H.; Liu, M.; Chen, J.; Zhu, H.; Chow, M.; Hersh, L.B.; Despa, F. Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1beta Synthesis in Brains of Alzheimer’s Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats. J. Alzheimers Dis.; 2016; 53, pp. 259-272. [DOI: https://dx.doi.org/10.3233/JAD-160047] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27163815]